M. C. Wong, W. B. Goggins, and H. H. Wang, Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries, Eur Urol, vol.70, pp.862-874, 2016.

J. F. Ward and J. W. Moul, Rising prostate-specific antigen after primary prostate cancer therapy, Nat Clin Pract Urol, vol.2, pp.174-182, 2005.

N. Mottet, J. Bellmunt, and M. Bolla, EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent, Eur Urol, vol.71, pp.618-629, 2016.

L. Evangelista, A. Briganti, and S. Fanti, New clinical indications for (18) F/(11)C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature, Eur Urol, vol.70, pp.161-175, 2016.

M. Eiber, T. Maurer, and M. Souvatzoglou, Evaluation of hybrid (6)(8) Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy, J Nucl Med, vol.56, pp.668-674, 2015.

M. Eder, O. Neels, and M. Müller, Novel preclinical and radiopharmaceutical aspects of [(68)Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer, Pharmaceuticals, vol.7, pp.779-796, 2014.

W. P. Fendler, M. Eiber, and M. Beheshti, 68Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0, Eur J Nucl Med Mol Imaging, vol.44, pp.1014-1024, 2017.

A. Afshar-oromieh, C. M. Zechmann, and A. Malcher, Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-cholinebased PET/CT for the diagnosis of recurrent prostate cancer, Eur J Nucl Med Mol Imaging, vol.41, pp.11-20, 2014.

J. J. Morigi, P. D. Stricker, and P. J. Van-leeuwen, Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising psa after curative treatment and are being considered for targeted therapy, J Nucl Med, vol.56, pp.1185-1190, 2015.

C. Bluemel, M. Krebs, and B. Polat, 68Ga-PSMA-PET/CT in patients with biochemical prostate cancer recurrence and negative 18FCholine-PET/CT, Clin Nucl Med, vol.41, pp.515-521, 2016.

M. Gauthé, O. Belissant, and A. Girard, TEP/TDM et récidive biologique d'adénocarcinome prostatique: apport du 68 Ga-PSMA-11 lorsque la 18 F-fluorocholine n'est pas contributive, Prog Urol, vol.27, pp.474-481, 2017.

S. Han, S. Woo, Y. J. Kim, and C. H. Suh, Impact of 68 Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis, Eur Urol, vol.74, pp.179-190, 2018.

J. J. Tosoian, M. A. Gorin, A. E. Ross, K. J. Pienta, P. T. Tran et al., Oligometastatic prostate cancer: definitions, clinical outcomes and treatment considerations, Nat Rev Urol, vol.14, pp.15-25, 2017.

F. Rozet, C. Hennequin, and J. Beauval, Recommandations en oncourologie 2016-2018 du CCAFU: cancer de la prostate, Prog En Urol, vol.27, pp.95-143, 2016.
DOI : 10.1016/s1166-7087(16)30705-9

B. Al,

N. Woythal, R. Arsenic, and C. Kempkensteffen, Immunohistochemical validation of PSMA expression measured by 68Ga-PSMA PET/CT in primary prostate cancer, J Nucl Med, vol.59, pp.238-243, 2018.

S. Medina-ornelas-sevastián, G. Francisco, O. , H. Norma, Y. et al., Correlación entre el volumen molecular tumoral evaluado con PET/TC con 68 Ga-PSMA y los niveles de antígeno prostático específico, Rev Esp Med Nucl E Imagen Mol, vol.37, pp.223-228, 2018.

J. S. Ross, K. E. Gray, and I. J. Webb, Antibody-based therapeutics: focus on prostate cancer, Cancer Metastasis Rev, vol.24, pp.521-537, 2005.

I. Rauscher, M. Eiber, W. A. Weber, J. E. Gschwend, T. Horn et al., Positron-emission tomography imaging in urological oncology: current aspects and developments, Int J Urol, 2018.

M. Barbaud, M. Frindel, and L. Ferrer, 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes, The Prostate, pp.1-8, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01980821

,